Social networks
5,630Activities
Technologies
Entity types
Location
Lunastigen 5, 141 44 Huddinge, Sweden
Huddinge
Sweden
Employees
Scale: 2-10
Estimated: 45
Engaged corporates
0Added in Motherbase
1 year, 11 months agoImproving life for cancer patients through transformative drugs
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.
Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.
Pharmaceuticals, Oncology, Biotech, and Clinical development
Medivir is a drug discovery and development company focusing on transformative cancer drugs. Our research and development are based on our extensive expertise in protease inhibitor design and nucleoside/nucleotide science. Science working wonders.